Dr. Hui-Ling Lin is a Professor of Respiratory Therapy at Chang Gung University and a leading expert in aerosol medicine, respiratory therapy, and biomedical engineering. She holds a PhD in Biomedical Engineering and Environmental Science from National Tsing Hua University, Taiwan (2022), an Masters of Science in Cardiopulmonary Sciences from Georgia State University, USA (2005), and a Bachelor of Science  in Respiratory Care from Dakota State University, USA (2003). 

With over two decades of experience, Dr. Lin has made significant contributions to aerosolized drug delivery, respiratory therapy devices, and treatment optimization for critically ill patients. Her groundbreaking research has led to advancements in aerosol drug quantification, drug delivery during mechanical ventilation, and smart nebulizer technology. She has authored over 70 peer-reviewed publications and text-book chapters, presented at international conferences, and holds four patents in aerosol delivery systems.

Dr. Lin collaborates with leading experts in the U.S, Taiwan, and China, enhancing aerosol therapy for both spontaneously breathing and mechanically ventilated patients both in pediatric and adults. She is currently focused on developing smart nebulizer technology to improve precision drug delivery.

With over 20 years of experience in respiratory care and aerosol research, Dr. Lin has focused on advancing aerosolized drug delivery, optimizing mechanical ventilation strategies, and developing innovative respiratory therapy devices. Her research has led to significant breakthroughs in aerosol drug quantification, the impact of humidification on aerosol delivery, and drug deposition in different respiratory support settings. She has pioneered methods to enhance aerosolized drug delivery efficiency for mechanically ventilated patients, spontaneously breathing individuals, and those using high-flow nasal cannula systems.

Dr. Lin’s respiratory research loab focuses:

• Aerosolized drug delivery during mechanical ventilation, particularly optimizing delivery efficiency for inhaled antibiotics and bronchodilators both in adulat and pediatric brathing patterns.
• Development of smart nebulizer technology, integrating breath-triggered mechanisms and reducing residual drug waste.
• Reformulation of dry powder inhalers to enhance deposition efficiency across different respiratory support modalities.
• Use of high-flow nasal cannula for aerosol drug delivery, investigating particle size distribution and clinical efficacy.
• Aerosol-drug interactions with biofilms, focusing on improving antibiotic penetration for drug-resistant infections.